REGN · News · 20260805N

Competition and Market Share

REGENERON PHARMACEUTICALS, INC. · 2026-08-05 · Importance 34 · Surprise 42

Regeneron faces new biosimilar competition for Eylea, one of its key ophthalmology products. The competitive pressure is relevant to both standard-dose Eylea and the company’s broader ophthalmology franchise, which also includes Eylea HD. Third-party coverage identifies Eylea competition as a key commercial risk for Regeneron.

Key facts